Biogen: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
[[Category:1978 establishments in Massachusetts]] | [[Category:1978 establishments in Massachusetts]] | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Biogen.svg|Biogen | |||
File:Biogen.jpg|Biogen | |||
</gallery> | |||
Latest revision as of 00:49, 20 February 2025
Biogen is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.
History[edit]
Biogen was founded in 1978 by several prominent biologists, including Nobel Prize winners Walter Gilbert and Phillip Sharp. The company's name is a portmanteau of "biological" and "genetic".
Products and Services[edit]
Biogen's products are focused on treating diseases in the areas of neurology, immunology, and hematology. Some of their most well-known products include Tecfidera, Avonex, and Tysabri, which are used to treat multiple sclerosis, and Spinraza, which is used to treat spinal muscular atrophy.
Research and Development[edit]
Biogen has a robust research and development program, with a focus on neurology and neurodegenerative diseases. The company is also involved in the research and development of therapies for autoimmune diseases and hematology.
Controversies[edit]
Biogen has faced several controversies over the years, including lawsuits related to patent infringement and pricing of their products.
See Also[edit]
References[edit]
<references />
